Regenerative therapies with cardiac and vascular applications represent one of the most promising options in the fight against cardiovascular failure. Since 2004, the International Symposium on Cell Therapy and Cardiovascular Innovations (TECAM, www.cardiovascularcelltherapy.com) has been held in Spain on a yearly basis to gather the most important research groups of clinicians and scientists worldwide and to discuss the progress and hurdles of Cardiovascular Regenerative Medicine (CRM) in an open forum. The latest edition of the TECAM conference took place in Madrid on June the 15th and the 16th. Recent breakthroughs and future steps were debated during the meeting, with a special focus on the most recent achievements of the Transnational AllianCe for regenerative Therapies In Cardiovascular Syndromes (TACTICS, www.tacticsalliance.org) group and are summarized in this article. The opening session started with a keynote conference delivered by Dr Michael Laflamme, who reflected on the difficulties for obtaining real cardiac regeneration with old types of stem cells. He therefore focused his talk on pluripotent stem cells, the one cell type that has demonstrated robust differentiation into cardiomyocytes. After presenting the important functional benefits of human embryonic stem cell (ESC)–derived cardiomyocytes in murine models and recognizing safety concerns (ie, ventricular arrhythmias) in primates and swine models of myocardial scar, he concluded that large-scale remuscularization is possible using this type of human-derived cells. In the second talk, Dr Juan Carlos Izpisúa presented the latest approaches to manipulate the genome in cells that do not divide. After describing how CRISPR/Cas9 can be used to induce double-strand breaks and nonhomologous end joining-based repair on the DNA, he explained the Homology Independent Targeted Integration technology that has been designed by his group. This novel tool for gene editing has been used to correct mutations in nondividing cells such as neurons and cardiomyocytes, with impressive …

中文翻译：

---

第十四届干细胞治疗与心血管创新国际研讨会概况

心脏和血管应用的再生疗法是对抗心血管衰竭的最有前途的选择之一。自2004年以来，每年在西班牙举行的国际细胞治疗和心血管创新专题讨论会（TECAM，www.cardiovascularcelltherapy.com）聚集了全世界最重要的临床医生和科学家研究小组，并讨论了该领域的进展和障碍。公开论坛中的心血管再生医学（CRM）。最新版本的TECAM会议于6月15日至16日在马德里举行。会议期间讨论了近期的突破和未来的步骤，特别关注跨国集团在心血管综合征再生疗法方面的最新成就（TACTICS，www.tacticsalliance。org）组，并在本文中进行了总结。开幕式首先由Michael Laflamme博士主持的主题会议开始，他回顾了使用旧类型的干细胞获得真正的心脏再生的困难。因此，他将演讲的重点放在了多能干细胞上，这种多能干细胞已显示出向心肌细胞的强大分化能力。在展示了人类胚胎干细胞（ESC）衍生的心肌细胞在鼠模型中的重要功能优势，并认识到灵长类和猪心肌瘢痕模型中的安全性问题（即室性心律失常）后，他得出结论，使用该模型可以进行大规模的肌肉再生人源细胞的类型。在第二次演讲中，Juan CarlosIzpisúa博士介绍了在不分裂的细胞中操纵基因组的最新方法。在描述了如何使用CRISPR / Cas9诱导DNA上的双链断裂和基于非同源末端连接的修复后，他解释了他的团队设计的同源独立靶向整合技术。这种用于基因编辑的新颖工具已被用于纠正非分裂细胞（如神经元和心肌细胞）中的突变，令人印象深刻……